Founded in 2017, Fujian ComHony Biotechnology Co., Ltd. is a high-end biomedical enterprise integrating R&D, production, and sales. With a total investment of RMB 600 million, the company's facility occupies 83 mu (approximately 55,333 m²) of production land and a total construction area of 35,707.89 m².

Facilities & Capabilities

The company operates dedicated workshops for biological culture, drug purification, drug synthesis, and drug refinement, as well as professional warehouses and a purpose-built R&D engineering center. Core equipments and processes meet international advanced standards, with cutting-edge of automated production. The production environments are managed in strict accordance with GMP requirements, backed by advanced analytical instruments and a seasoned technical team.

Product Portfolio

ComHony's product range covers more than 20 varietires accrodss four categories:

· Anti-Biotics APIs (Mupirocin Base/ Calcium, Fusidic Acid/ Sodium, Amikacin Sulfate, Daptomycin, Dalbavancin HCL)

· Veterinary APIs (Kanamycin Monosulfate)

· Nutraceutical Raw Materials (PQQ Disodium Salt, Ergothioneine)

· Intermediate (Mycophenolic Acid MPA, Demeclocycline Hydrochloride)

Intellectual Property & Recognition

The company holds 10 invention patents and 36 authorized utility model patents, and has been recognized as a National High-Tech Enterprise. It has also been designated a "Specialized, Sophisticated, Unique and Innovative" SME by Fujian Province.

Certifications & Regulatory Compliance

As a globally oriented API production base, ComHony has achieved an extensive portfolio of certifications and regulatory approvals:

·  Manufacturing Certifications: EU-GMP, ISO series, NSF-GMP, Kosher, Halal

·  Product Certifications: CEP, COPP, WC

·  Regulatory Registrations: EDQM, US FDA, China NMPA

Strategic Outlook

Looking ahead, ComHony will expand its pipeline into anti-tumor therapeutics, next-generation anti-infectives, and functional medical foods. Committed to green and sustainable development, the company is building toward a world-class brand in the global biotechnology industry.